New research suggests that a promising herpes vaccine may be ready for testing in humans say researchers from the National Institutes of Health and Harvard Medical School. Their findings appear in the January 2005 issue of the Journal of Virology.
Herpes simplex virus type 2 (HSV-2), or genital herpes, is a virus that infects approximately 22% of adult Americans. Bearing physical, psychological, and social effects on those who acquire it, it can pose an even more severe risk for immuno-compromised patients further emphasizing the need for an effective vaccine. "In the aggregate, the burden of genital herpes has made development of more effective prevention strategies a health priority," say the researchers.
The study compared three different vaccines, a DNA vaccine, an antigenic vaccine and a live mutant strain of the type 2 virus, d15-29, in mice and guinea pigs. The live mutant strain, d15-29, showed minimal risk of causing disease as it is missing two of the genes necessary for replication and it stimulated a stronger immune response in both animals. "Given its efficacy, its defectiveness for latency, and its ability to induce rapid, virus-specific CD8+T-cell responses, the dl5-29 vaccine may be a good candidate for early-phase human trials," say the researchers.
Jim Sliwa | EurekAlert!
Hepatitis: liver failure attributable to compromised blood supply
19.12.2018 | Technische Universität München
Collagen nanofibrils in mammalian tissues get stronger with exercise
14.12.2018 | University of Illinois College of Engineering
Different eras of civilization are defined by the discovery of new materials, as new materials drive new capabilities. And yet, identifying the best material...
Researchers from the University of Basel have reported a new method that allows the physical state of just a few atoms or molecules within a network to be controlled. It is based on the spontaneous self-organization of molecules into extensive networks with pores about one nanometer in size. In the journal ‘small’, the physicists reported on their investigations, which could be of particular importance for the development of new storage devices.
Around the world, researchers are attempting to shrink data storage devices to achieve as large a storage capacity in as small a space as possible. In almost...
The more objects we make "smart," from watches to entire buildings, the greater the need for these devices to store and retrieve massive amounts of data quickly without consuming too much power.
Millions of new memory cells could be part of a computer chip and provide that speed and energy savings, thanks to the discovery of a previously unobserved...
What if, instead of turning up the thermostat, you could warm up with high-tech, flexible patches sewn into your clothes - while significantly reducing your...
A widely used diabetes medication combined with an antihypertensive drug specifically inhibits tumor growth – this was discovered by researchers from the University of Basel’s Biozentrum two years ago. In a follow-up study, recently published in “Cell Reports”, the scientists report that this drug cocktail induces cancer cell death by switching off their energy supply.
The widely used anti-diabetes drug metformin not only reduces blood sugar but also has an anti-cancer effect. However, the metformin dose commonly used in the...
12.12.2018 | Event News
10.12.2018 | Event News
06.12.2018 | Event News
19.12.2018 | Materials Sciences
19.12.2018 | Materials Sciences
19.12.2018 | Life Sciences